Explore

Trendline Trendline
Bank of America Allocates $250 Million Annually for Employee Weight Loss Drugs

Bank of America Allocates $250 Million Annually for Employee Weight Loss Drugs

Bank of America Allocates $250 Million Annually for Employee Weight Loss Drugs
Trendline Trendline
Bank of America Allocates Over $250 Million Annually for Employee Weight-Loss Drugs

Bank of America Allocates Over $250 Million Annually for Employee Weight-Loss Drugs

Bank of America Allocates Over $250 Million Annually for Employee Weight-Loss Drugs
USA Today USA Today
Bank of America spends $250M yearly on GLP-1s for workers, CEO says

Bank of America spends $250M yearly on GLP-1s for workers, CEO says

Bank of America's CEO said the company spends more than $250 million a year on GLP-1 drugs for employees, calling the growing cost a worthwhile investment.
Trendline Trendline
Bank of America Commits $250 Million Annually to Employee Weight-Loss Medication

Bank of America Commits $250 Million Annually to Employee Weight-Loss Medication

Bank of America Commits $250 Million Annually to Employee Weight-Loss Medication
Trendline Trendline
Bank of America Continues $250 Million Investment in Employee Weight-Loss Medications

Bank of America Continues $250 Million Investment in Employee Weight-Loss Medications

Bank of America Continues $250 Million Investment in Employee Weight-Loss Medications
Trendline Trendline
Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health

Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health

Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health
Trendline Trendline
Bank of America Invests $250 Million Annually in GLP-1 Weight-Loss Medications for Employees

Bank of America Invests $250 Million Annually in GLP-1 Weight-Loss Medications for Employees

Bank of America Invests $250 Million Annually in GLP-1 Weight-Loss Medications for Employees
Trendline Trendline
Starbucks Ends GLP-1 Coverage for Weight Loss Amid Rising Costs

Starbucks Ends GLP-1 Coverage for Weight Loss Amid Rising Costs

Starbucks Ends GLP-1 Coverage for Weight Loss Amid Rising Costs
Trendline Trendline
Novo Nordisk CEO Resets Expectations for Wegovy's Growth Amid Market Competition

Novo Nordisk CEO Resets Expectations for Wegovy's Growth Amid Market Competition

Novo Nordisk CEO Resets Expectations for Wegovy's Growth Amid Market Competition
Trendline Trendline
Bank of America Invests Over $250 Million in Employee Health with GLP-1 Drugs

Bank of America Invests Over $250 Million in Employee Health with GLP-1 Drugs

Bank of America Invests Over $250 Million in Employee Health with GLP-1 Drugs
Trendline Trendline
Bank of America Invests $250 Million Annually in Employee Health with GLP-1 Drugs

Bank of America Invests $250 Million Annually in Employee Health with GLP-1 Drugs

Bank of America Invests $250 Million Annually in Employee Health with GLP-1 Drugs
Trendline Trendline
Bank of America CEO Warns of Risks in Leveraged Markets Following Hedge Fund Collapse

Bank of America CEO Warns of Risks in Leveraged Markets Following Hedge Fund Collapse

Bank of America CEO Warns of Risks in Leveraged Markets Following Hedge Fund Collapse